{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T23:02:33Z","timestamp":1789945353397,"version":"4.0.1"},"reference-count":22,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2018,3,6]],"date-time":"2018-03-06T00:00:00Z","timestamp":1520294400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2018,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objectives<\/jats:title><jats:p>To investigate the efficacy, safety, and cost of a pomalidomide\u2010dexamethasone regimen in patients with relapsed and refractory multiple myeloma (RRMM).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>All patients (n\u00a0=\u00a063) treated with pomalidomide\u2010dexamethasone for RRMM in our university hospital between August 2013 and October 2015 were included.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Pomalidomide was discontinued early due to progression (before the 4th cycle) in 17 (27%) patients. No case was discontinued for intolerance. The only independent factor that predicted early pomalidomide discontinuation was time from diagnosis to pomalidomide initiation &lt;3\u00a0years. Overall response rate was 51% including complete response in 8%, very good partial response in 25%, and partial response in 19% patients. Thirteen (33%) patients showed stable disease. Median overall survival was 6.4\u00a0months in the 17 patients who discontinued pomalidomide early vs 26.8\u00a0months in the 14 patients with stable disease vs not achieved in the 32 responders (log\u2010rank; <jats:italic>P<\/jats:italic>\u00a0&lt;\u00a010<jats:sup>\u22123<\/jats:sup>). The most common grade \u22653 adverse events were neutropenia (14%) and infections (25%). The incremental cost\u2010effectiveness ratio of pomalidomide\u2010dexamethasone compared with dexamethasone alone was estimated at \u20ac39\u00a0911 per life\u2010year gained.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The study demonstrated that pomalidomide\u2010dexamethasone regimen has a long\u2010term favorable safety\u2010efficacy profile in RRMM patients. The survival benefit is substantial even in patients with stable disease.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ejh.13039","type":"journal-article","created":{"date-parts":[[2018,2,2]],"date-time":"2018-02-02T13:12:45Z","timestamp":1517577165000},"page":"518-525","source":"Crossref","is-referenced-by-count":16,"title":["Efficacy, safety, and cost of pomalidomide in relapsed and refractory multiple myeloma"],"prefix":"10.1111","volume":"100","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7328-8135","authenticated-orcid":false,"given":"Pauline","family":"Gueneau","sequence":"first","affiliation":[{"name":"Pharmacy Department University Hospital  Dijon France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie\u2010Lorraine","family":"Chretien","sequence":"additional","affiliation":[{"name":"Haematology Department University Hospital  Dijon France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amelie","family":"Cransac\u2010Miet","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Dijon University Hospital and LNC UMR1231 Burgundy&amp;Franche Comt\u00e9 University  Dijon France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludwig Serge","family":"Aho","sequence":"additional","affiliation":[{"name":"Epidemiology Department University Hospital  Dijon France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Lafon","sequence":"additional","affiliation":[{"name":"Haematology Department University Hospital  Dijon France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Favennec","sequence":"additional","affiliation":[{"name":"Haematology Department University Hospital  Dijon France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Guy","sequence":"additional","affiliation":[{"name":"Haematology Laboratory University Hospital  Dijon France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Caillot","sequence":"additional","affiliation":[{"name":"Haematology Department University Hospital  Dijon France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Boulin","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Dijon University Hospital and LNC UMR1231 Burgundy&amp;Franche Comt\u00e9 University  Dijon France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,3,6]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra041875"},{"key":"e_1_2_5_3_1","unstructured":"GLOBOCAN.Cancer Incidence Mortality and Prevalence Worldwide[Internet]. GLOBOCAN 2012.http:\/\/globocan.iarc.fr\/old\/burden.asp?selection_pop=224900&Text-p=World&selection_cancer=17270&Textc=Multiple+myeloma&pYear=3&type=1&window=1&submit=%C2%A0Execute. Accessed September 25 2017."},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.4600"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.196"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-54490-3_22"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70380-2"},{"key":"e_1_2_5_8_1","first-page":"204","article-title":"Estimating the costs of therapy in patients with relapsed and\/or refractory multiple myeloma: a model framework","volume":"8","author":"Roy A","year":"2015","journal-title":"Am Health Drug Benefits"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70442-5"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-10-299487"},{"key":"e_1_2_5_11_1","unstructured":"National Cancer Institute National Institutes of Health.Common Terminology criteria for Adverse Events (CTCAE). CTCAE 4.02. Version 4.02 [Internet]. National Institutes of Health. 2009.http:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/Archive\/CTCAE_4.02_2009-09-15_QuickReference_8.5x11.pdf. Accessed April 24 2016."},{"key":"e_1_2_5_12_1","unstructured":"Legifrance. Avis relatif aux prix de sp\u00e9cialit\u00e9s pharmaceutiques publi\u00e9s en application de l'article L. 162\u201016\u20105 du code de la s\u00e9curit\u00e9 sociale. NOR\u202f: AFSS1417207V [Internet]. legifrance.gouv.fr. 2014.https:\/\/www.legifrance.gouv.fr\/jo_pdf.do?id=JORFTEXT000029308538. Accessed April 24 2016."},{"key":"e_1_2_5_13_1","unstructured":"WHO.Thresholds for the cost\u2013effectiveness of interventions: alternative approaches[Internet]. WHO.http:\/\/www.who.int\/bulletin\/volumes\/93\/2\/14-138206\/en\/. Accesssed September 25 2017"},{"key":"e_1_2_5_14_1","unstructured":"GDP per capita (current US$) | Data[Internet].https:\/\/data.worldbank.org\/indicator\/NY.GDP.PCAP.CD. Accessed Sesptember 25 2017."},{"key":"e_1_2_5_15_1","unstructured":"EMA. Europa. European Medicines Agency \u2010 Find medicine \u2010 Imnovid[Internet].http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/002682\/human_med_001669.jsp&mid=WC0b01ac058001d124. Accessed June 18 2016."},{"key":"e_1_2_5_16_1","unstructured":"NICE.NICE issues final guidance on pomalidomide (Imnovid) for blood cancer | Press and media | News | NICE[Internet]. 2015.https:\/\/www.nice.org.uk\/news\/press-and-media\/nice-issues-final-guidance-on-pomalidomide-imnovid-for-blood-cancer. Accessed June 15 2016."},{"key":"e_1_2_5_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-538835"},{"key":"e_1_2_5_18_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2016.1180685"},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-11-612069"},{"key":"e_1_2_5_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2405062"},{"key":"e_1_2_5_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-02-700872"},{"key":"e_1_2_5_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12903"},{"key":"e_1_2_5_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2017.08.010"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fejh.13039","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.13039","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T16:04:24Z","timestamp":1695571464000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.13039"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,6]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["10.1111\/ejh.13039"],"URL":"https:\/\/doi.org\/10.1111\/ejh.13039","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,6]]}}}